Almost nothing in a small company's filings comes with a date attached. A going concern paragraph says the company may not survive, but not when. A shelf says shares may be sold, but not on which day. The exchange listing clock is the exception. It has a start, a length, and an end, and all three are public.
If a Nasdaq-listed stock closes below $1.00 for 30 consecutive business days, the exchange sends a deficiency notice and the company must disclose it, usually on Form 8-K within four business days. The company then has 180 calendar days to regain compliance, which means closing at or above $1.00 for at least ten consecutive business days. Nasdaq Capital Market companies that meet the other listing standards can receive a second 180-day period if they tell the exchange how they intend to cure, most often by reverse split. Miss the last deadline and the stock moves to a hearing, then to OTC. Losing the listing narrows a company's financing options at the moment it most needs them.
Nasdaq's continued listing standards require a minimum closing bid price of $1.00. The test is not a single bad day. The clock starts when the closing bid has been below $1.00 for 30 consecutive business days. On or shortly after the thirtieth day the exchange's Listing Qualifications staff sends a deficiency notice, and the stock keeps trading on Nasdaq while the company works on a cure.
The notice is not private. Exchange rules require the company to announce it, and a Form 8-K is the usual vehicle, filed within four business days of receipt. That filing is the first dated fact most investors see, and it is the one that shows up in every screen of the company from then on.
From the notice the company has 180 calendar days to regain compliance. Compliance means the closing bid price is at or above $1.00 for at least ten consecutive business days, and the exchange can require a longer stretch if it has concerns about whether the price will hold. Nothing else has to change. A company can cure by trading, by buying back stock, by a strategic announcement that reprices the equity, or by the one mechanical tool that always works on the number: a reverse split.
A reverse split cures the bid price by dividing the share count. It changes nothing about the business, and the market knows it. Investors' historical experience with reverse splits in micro-caps is poor enough that the announcement itself can push the pre-split price lower. That is why the best cure is the one that comes from the business, and why companies with a real story try to tell it inside the 180 days rather than default to the split.
A company listed on the Nasdaq Capital Market can receive a second 180-day period if, at the end of the first, it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards except the bid price, and it notifies the exchange in writing of its intent to cure, typically by reverse split, during the second period. Nasdaq Global Market and Global Select companies do not get the automatic second period; they can transfer to the Capital Market to seek one.
Nasdaq has tightened this path in recent years. A company whose bid price deficiency follows a reverse split it completed within the prior year is not eligible for a compliance period at all and receives a delisting determination it can appeal but not wait out. The practical reading is simple: the exchange will give a company time once, and it will not let a company split its way to compliance on a loop.
If the final deadline passes without compliance, the staff issues a delisting determination. The company can request a hearing before a Nasdaq Hearings Panel, and the request generally stays the delisting until the panel decides. Panels can grant additional time, up to an outside limit of 360 days from the original notice, if the company presents a credible plan. If the stock is delisted it typically begins trading on the OTC markets, and the company's disclosure obligations under the Exchange Act continue.
NYSE American runs an analogous regime under its own continued listing standards, with a different mechanism: the exchange evaluates low selling prices over a sustained period and can require a reverse split within a set time. The dated structure is similar in spirit. The Nasdaq version is simply more mechanical.
The reason the clock matters to a CFO is not the symbol. It is the money. A national exchange listing preempts state blue sky registration for many offerings, keeps the company eligible for a broader set of shelf and registered direct structures, and keeps it inside the mandates of funds that cannot hold unlisted securities. Lose the listing and the fastest routes to raising capital narrow at exactly the moment the company is weakest. That is the asymmetry the clock creates: the deadline is dated, the cure is usually dilutive, and the cost of missing it lands on the balance sheet, not on the stock chart.
This briefing pairs with Episode 16 of the Watchlist Wire podcast, The Delisting Clock, and with the capital structure section that every Watchlist Wire dossier carries. Dossiers note recent deficiency notices, cure periods, and reverse splits where they appear in the filings, because a company's financing options depend on them.
Nasdaq requires listed stocks to maintain a minimum closing bid price of $1.00. A company falls out of compliance when the closing bid is below $1.00 for 30 consecutive business days, at which point the exchange issues a deficiency notice.
180 calendar days from the deficiency notice. Compliance is regained when the closing bid is at or above $1.00 for at least ten consecutive business days. Nasdaq Capital Market companies that meet the other listing standards can receive a second 180-day period if they notify the exchange of their intent to cure.
Mechanically, yes: dividing the share count raises the per-share price. It does not change the business, and Nasdaq no longer grants a compliance period to a company whose deficiency follows a reverse split completed within the prior year.
The stock typically moves to the OTC markets. The company's reporting obligations continue, but it loses the state law preemption and the eligibility for certain offering structures and fund mandates that come with a national exchange listing, which makes raising capital slower and more expensive.
Every Watchlist Wire dossier covers capital structure, dilution history, and listing status, sourced to the filings.
See the research library Listen to Episode 16